ArticleIJU case reports2026
Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin-4 Expression: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcomatoid urothelial carcinoma (UC) is an extremely rare and aggressive subtype with a poor prognosis. Reports on the efficacy of enfortumab vedotin (EV) in this subtype remain limited. Case Presentation: A 74-year-old man presented with gross hematuria and was diagnosed with metastatic sarcomatoid UC of the urinary bladder with Nectin-4 expression. First-line chemotherapy with gemcitabine plus carboplatin therapy was initiated; however, lymph node metastases progressed. After second-line pembrolizumab therapy, new pulmonary and para-aortic lymph node metastases developed. Third-line EV therapy achieved a partial response in the bladder cancer and complete response in metastatic lesions. The patient subsequently underwent robot-assisted radical cystectomy with ileal conduit diversion, and pathological examination revealed no residual carcinoma (ypT0N0). He has remained disease-free for 30 months without additional therapy. Conclusion: EV may induce substantial and clinically meaningful responses in selected patients with metastatic sarcomatoid UC expressing Nectin-4, even after failure of platinum-based chemotherapy and immune checkpoint inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.